KINETIC-ANALYSIS OF TISSUE DISTRIBUTION OF DOXORUBICIN INCORPORATED IN LIPOSOMES IN RATS .1.

被引:12
作者
HARASHIMA, H
OHSHIMA, S
MIDORI, Y
YACHI, K
KIKUCHI, H
KIWADA, H
机构
[1] UNIV TOKUSHIMA,FAC PHARMACEUT SCI,1-78-1 SHOMACHI,TOKUSHIMA 770,JAPAN
[2] DAIICHI PHARMACEUT CO LTD,DEV LABS,EDOGAWA KU,TOKYO 134,JAPAN
关键词
DOXORUBICIN; LIPOSOMES; PHARMACOKINETICS; CLEARANCE;
D O I
10.1002/bdd.2510130302
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to perform a kinetic analysis of the tissue distribution of doxorubicin (DXR) and liposomes separately after intravenous administration of DXR entrapped in liposomes in rats. Liposomes were double labeled with 14C-DXR (L-DXR) and 3H-inulin (L-INU). Blood and tissues were sampled at specified times until 120 min. Blood clearance of L-DXR was similar to that of L-INU. Distribution of both L-DXR and L-INU into the liver was parallel and extensive, while in the heart, the pattern of distribution differed between L-DXR and L-INU after peak concentration. Time courses of tissue concentration were explained well by dividing tissue into a shallow compartment with efflux and a deep compartment without efflux. In the liver, pharmacokinetic parameters of L-DXR and L-INU were similar, and the two kinetically different compartments may correspond to different uptake processes in hepatic endocytosis. In the heart, the shallow compartment was considered to correspond to the cardiac vascular space, and the intercompartmental rate constant (k3) for L-DXR was much larger than that for L-INU. The estimated half-life for this process was 20 min. The half-life for the degradation of liposomes in blood circulation was also estimated at 20 min from data on the urinary excretion of released 3H-inulin. These results suggest that the release of DXR from liposomes may be the rate-limiting process in the tissue distribution of DXR to the heart.
引用
收藏
页码:155 / 170
页数:16
相关论文
共 23 条
  • [1] DOXORUBICIN - EFFECT OF DIFFERENT SCHEDULES ON TOXICITY AND ANTI-TUMOR EFFICACY
    BIELACK, SS
    ERTTMANN, R
    WINKLER, K
    LANDBECK, G
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (05): : 873 - 882
  • [2] BOT MA, 1988, BIOCHEM PHARMACOL, V37, P3877
  • [3] CALABRESI P, 1990, GOODMAN GILMANS PHAR, P1241
  • [4] CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681
  • [5] SEPARATION OF LIPOSOME-ASSOCIATED DOXORUBICIN FROM NON-LIPOSOME-ASSOCIATED DOXORUBICIN IN HUMAN-PLASMA - IMPLICATIONS FOR PHARMACOKINETIC STUDIES
    DRUCKMANN, S
    GABIZON, A
    BARENHOLZ, Y
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1989, 980 (03) : 381 - 384
  • [6] FORSSEN EA, 1983, CANCER RES, V43, P546
  • [7] GABIZON A, 1983, CANCER RES, V43, P4730
  • [8] PHARMACOKINETICS AND TISSUE DISTRIBUTION OF DOXORUBICIN ENCAPSULATED IN STABLE LIPOSOMES WITH LONG CIRCULATION TIMES
    GABIZON, A
    SHIOTA, R
    PAPAHADJOPOULOS, D
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (19): : 1484 - 1488
  • [9] HARTMAN N, 1982, CANCER CHEMOTH PHARM, V10, P11
  • [10] ISRAEL M, 1978, CANCER RES, V38, P365